阿尔茨海默病的小鼠模型。
Mouse models of Alzheimer's disease.
机构信息
Center for Neurodegeneration and Experimental Therapeutics, Departments of Neurology and Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
出版信息
Brain Res Bull. 2012 May 1;88(1):3-12. doi: 10.1016/j.brainresbull.2011.11.017. Epub 2011 Nov 28.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia, affecting 35 million people today. The search for new treatments is made ever more urgent by prospects for increasing prevalence due to population aging. Mouse models are one of the most important research tools for finding new treatments for AD. Here, we review those models. We begin by briefly reviewing the AD genetics on which mouse models are based and then consider the most common mouse models of AD, including mice transgenic for human amyloid precursor protein (hAPP) and beta-amyloid (Aβ), mice expressing mutant presenilin genes, mice modeling tau's role in AD, and apolipoprotein E models. The discussion highlights key features and important differences between these mouse models. We conclude with a discussion about the role of AD mouse models in the translational pipeline.
摘要
阿尔茨海默病（AD）是痴呆症最常见的病因，目前影响着 3500 万人。由于人口老龄化，预计 AD 的患病率将会增加，因此对新疗法的探索变得更加紧迫。小鼠模型是寻找 AD 新疗法的最重要的研究工具之一。在这里，我们将对这些模型进行综述。我们首先简要回顾一下 AD 的遗传基础，然后考虑 AD 的最常见的小鼠模型，包括表达人淀粉样前体蛋白（hAPP）和β-淀粉样蛋白（Aβ）的转基因小鼠、表达突变早老素基因的小鼠、模拟 AD 中 tau 作用的小鼠以及载脂蛋白 E 模型。讨论强调了这些小鼠模型之间的关键特征和重要差异。最后，我们讨论了 AD 小鼠模型在转化研究中的作用。
相似文献
1
Mouse models of Alzheimer's disease.
Brain Res Bull. 2012 May 1;88(1):3-12. doi: 10.1016/j.brainresbull.2011.11.017. Epub 2011 Nov 28.
2
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Mol Neurodegener. 2020 Sep 14;15(1):53. doi: 10.1186/s13024-020-00393-5.
3
Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques.
Alzheimers Res Ther. 2018 Apr 24;10(1):40. doi: 10.1186/s13195-018-0370-2.
4
Alzheimer's disease amyloid-β pathology in the lens of the eye.
Exp Eye Res. 2022 Aug;221:108974. doi: 10.1016/j.exer.2022.108974. Epub 2022 Feb 21.
5
Alzheimer disease: mouse models pave the way for therapeutic opportunities.
Arch Neurol. 2000 Feb;57(2):176-81. doi: 10.1001/archneur.57.2.176.
6
Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
PLoS One. 2013 Nov 20;8(11):e80706. doi: 10.1371/journal.pone.0080706. eCollection 2013.
7
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.
Mol Neurodegener. 2020 Oct 19;15(1):60. doi: 10.1186/s13024-020-00399-z.
8
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.
J Neurosci. 2000 Jun 1;20(11):4050-8. doi: 10.1523/JNEUROSCI.20-11-04050.2000.
9
Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
Mol Neurodegener. 2018 Jan 16;13(1):2. doi: 10.1186/s13024-017-0234-4.
10
Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease.
J Neurosci. 2008 Nov 26;28(48):12877-86. doi: 10.1523/JNEUROSCI.4582-08.2008.
引用本文的文献
1
Differences in Learning Strategy Selection and Object Location Memory Impairments in APP/PS1 Mice.
Exp Neurobiol. 2025 Aug 31;34(4):156-167. doi: 10.5607/en25013.
2
Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer's disease: A meta-analysis 2015-2023.
J Alzheimers Dis. 2025 Aug 1;107(2):13872877251362212. doi: 10.1177/13872877251362212.
3
Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer's Disease.
Int J Mol Sci. 2025 Jun 10;26(12):5541. doi: 10.3390/ijms26125541.
4
Modeling Alzheimer's Disease: A Review of Gene-Modified and Induced Animal Models, Complex Cell Culture Models, and Computational Modeling.
Brain Sci. 2025 May 5;15(5):486. doi: 10.3390/brainsci15050486.
5
Shared early molecular mechanisms revealed in P301S and 5xFAD Alzheimer's disease mouse models.
Transl Psychiatry. 2025 Mar 26;15(1):97. doi: 10.1038/s41398-025-03321-7.
6
Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease.
Heliyon. 2024 Oct 18;10(20):e39571. doi: 10.1016/j.heliyon.2024.e39571. eCollection 2024 Oct 30.
7
The IGF System and Aging.
Endocr Rev. 2025 Mar 11;46(2):214-223. doi: 10.1210/endrev/bnae029.
8
Gene deletion of Pregnancy-associated Plasma Protein-A (PAPP-A) improves pathology and cognition in an Alzheimer's disease mouse model.
Exp Neurol. 2024 Dec;382:114976. doi: 10.1016/j.expneurol.2024.114976. Epub 2024 Sep 28.
9
Ezetimibe Lowers Risk of Alzheimer's and Related Dementias over Sevenfold, Reducing Aggregation in Model Systems by Inhibiting 14-3-3G::Hexokinase Interaction.
Aging Biol. 2024;2. doi: 10.59368/agingbio.20240028. Epub 2024 Jun 26.
10
Small data methods in omics: the power of one.
Nat Methods. 2024 Sep;21(9):1597-1602. doi: 10.1038/s41592-024-02390-8. Epub 2024 Aug 22.
本文引用的文献
1
Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.
J Neurosci. 2011 May 25;31(21):7691-9. doi: 10.1523/JNEUROSCI.6637-10.2011.
2
The many faces of tau.
Neuron. 2011 May 12;70(3):410-26. doi: 10.1016/j.neuron.2011.04.009.
3
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
4
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
5
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
6
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Nat Genet. 2011 May;43(5):436-41. doi: 10.1038/ng.801. Epub 2011 Apr 3.
7
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
Nat Genet. 2011 May;43(5):429-35. doi: 10.1038/ng.803. Epub 2011 Apr 3.
8
Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation.
J Neurosci. 2011 Feb 2;31(5):1688-92. doi: 10.1523/JNEUROSCI.2610-10.2011.
9
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
J Neurosci. 2011 Jan 12;31(2):700-11. doi: 10.1523/JNEUROSCI.4152-10.2011.
10
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.
Nat Rev Neurosci. 2011 Feb;12(2):65-72. doi: 10.1038/nrn2967. Epub 2010 Dec 31.
Zotero 插件